Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Official title

Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail

Overview

This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or without brain parenchymal involvement.

Detailed description

Primary Objective:

\- To assess if treatment with systemic intravenous high-dose methotrexate (HD-MTX) will result in an overall survival (OS) exceeding 12 weeks at 80% among patients with triple negative, HER2-positive, and hormone refractory metastatic breast cancer patients with leptomeningeal metastasis (LMD) with and without parenchymal brain involvement.

Secondary and Exploratory Objectives

* To describe the one-year survival in patients with LMD from metastatic breast cancer treated with HD-MTX. * To describe the overall progression free survival (PFS) in patients with LMD from metastatic breast cancer treated with HD-MTX. * To describe the tolerability of HD-MTX in patients with LMD from metastatic breast cancer. * To describe the cost of HD-MTX treatment in patients with LMD from metastatic breast cancer. * To investigate cytologic sterilization following HD-MTX in patients with LMD from metastatic breast cancer.

Interventions

• Drug High-dose Methotrexate (8 gm/m2; HD-MTX)
  Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease p

Primary outcome measures

• Overall Survival (at 12 weeks) [Time frame: 12 weeks]

Secondary outcome measures (5)

• One year survival [Time frame: 1 year]
• Progression Free Survival [Time frame: From date of first treatment to the time of systemic or neurologic progression of disease whichever occurs first, assessed up to 2 years]
• Tolerability of Treatment - Number of Grade 3 or Higher Adverse Events [Time frame: Up to 2 years]
• Number of Treatment Delays [Time frame: Up to 2 years]
• Number of Dose Reductions [Time frame: Up to 2 years]

Eligibility criteria

Inclusion criteria

• Adults (male and female) age >18
• Eastern Cooperative Group (ECOG) Performance Scale 0-1 (see Appendix I)
• Histologically or cytologically confirmed invasive breast cancer of the following subtype:
• TRIPLE NEGATIVE (ER-negative, PR-negative, and HER2-negative disease). Triple-negative patients will be defined per ASCO-CAP Guidelines.
• HER2-POSITIVE: HER2-positive patients will be defined per ASCO-CAP Guidelines.
• HORMONE REFRACTORY: Patients with ER/PR-positive disease according to ASCO-CAP guidelines above may be considered if they have disease progression after two lines of hormonal therapy (administered in the adjuvant or metastatic setting), or are deemed clinically hormone-resistant taking into consideration the rate of progression of disease or a short interval of time on first line hormonal therapy before progression. Clinically hormone-resistant patients MUST also be discussed with the Study Chair, Study co-chair or designee in advance for approval.

NOTE: ASCO-CAP guidelines state that ER and PR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. HER2-positive is defined as HER2 IHC 3+, ISH ≥ 2.0, or average HER2 copy number ≥ 6.0 signals.

NOTE: A patient who has a change in receptor status (e.g. PR negative to positive) may be stratified as triple negative or hormone positive, contrary to the most recent receptor testing, for the purposes of the study, based upon the clinical course at the discretion of the Study Chair, Study co-chair, or designee in advance for approval.

• Cytologic or unequivocal radiographic confirmation of leptomeningeal metastasis by dural puncture and/or neuroimaging with or without known brain metastasis
• Adequate organ function as follows:

Estimated creatinine clearance >70 cc/min (calculated by Cockcroft-Gault formula) White blood cell counts >3000 cells/mcL Absolute neutrophil count >1500 cells/mcL Platelet count >100,000 cells/mcL Hematocrit >30% Serum bilirubin <1.5 x the ULN or <5x the ULN if secondary to liver metastasis Alanine aminotransferase or aspartate aminotransferase <2.5x the ULN or <5x the ULN if secondary to liver metastasis Alkaline phosphatase <2.5x the ULN or <5x the ULN if secondary to liver metastasis

\- Able to provide confirmed consent

Exclusion criteria

• Prior allergy or adverse reaction to methotrexate
• New York Heart Association Heart Failure Class >3
• Active diabetes insipidus
• Active mucositis
• Chemotherapy or stereotactic radiotherapy within the last 2 weeks
• Partial brain radiotherapy (i.e. <40% of total brain volume) within the last 2 weeks
• Whole brain radiotherapy within the last 6 months or partial brain radiotherapy exceeding >40% of total brain volume within the last 6 months
• Prior treatment with any methotrexate containing systemic regimen within 1 year (excluding intrathecal methotrexate)
• Concurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti- HER2 directed therapy directed at management of breast cancer (existing anti-HER2 therapy can be continued as recently recommended in the National Consensus Guidelines (26)
• Uncontrolled or progressive systemic disease or other concurrent condition which in the Investigator's opinion makes HD-MTX an undesirable treatment option for the patient or would jeopardize compliance
• Contraindication to MRI
• Use of salicylates, non-steroidal anti-inflammatory drugs, or sulfonamide medications within one week of start of methotrexate
• Pregnant women or women who are breastfeeding.
• Patients with significant visceral fluid collections including ascites, pericardial effusions, pleural effusions or others may experience delayed clearance of methotrexate because of third space accumulation which could result in methotrexate toxicity and inability to tolerate the proposed study treatment. While these are not absolute exclusions the Study Chair or co-Chairs should be contacted to discuss possible enrollment. Patients with significant ascites defined as European Association for the Study of the Liver > grade 2 (Appendix IV), or with asymptomatic pleural effusions with an estimated size >200 mL, or with symptomatic pleural effusion of any size will be excluded.

NOTE: Systemic staging of the chest/abdomen/pelvis is required for study entry. See Sections 8.1.9. Body fluid will be assessed based on this study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 3 centers

• Sidney Kimmel Comprehensive Cancer Center — Baltimore
• Siteman Cancer Center- Washington University School of Medicine in St. Louis — St Louis
• Comprehensive Cancer Center at Wake Forest University (CCCWFU) — Winston-Salem

Identifiers

NCT: NCT02422641 · IRB00035551 · P30CA012197 · CCCWFU 74315

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗